Tacoma、WAにおける非小細胞肺癌の臨床試験
Tacomaとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Northwest Medical Specialties Tacoma /ID# 270534, Tacoma
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
被験者募集中第1/2相
- Northwest Medical Specialties Tacoma /ID# 270469, Tacoma
- Vista Oncology - East Olympia /ID# 275438, Olympia · 26マイル先
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
被験者募集中第3相
- Northwest Medical Specialties - Tacoma, Tacoma
- Northwest Medical Specialties - Gig Harbor, Gig Harbor · 8マイル先
- Northwest Medical Specialties - Puyallup Medical Oncology, Puyallup · 8マイル先
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
被験者募集中第3相
- American Oncology Network Vista Oncology Division-West office, Olympia · 26マイル先
- American Oncology Network Vista Oncology Division-East office, Olympia · 26マイル先
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
被験者募集中第3相
- Vista Oncology Inc PS, Olympia · 26マイル先
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Vista Oncology, Olympia · 26マイル先
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
被験者募集中第3相
- American Oncology Network Vista Oncology Division-West office, Olympia · 26マイル先
- American Oncology Network Vista Oncology Division-East office, Olympia · 26マイル先
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
被験者募集中第1/2相
- Northwest Medical Specialties, Tacoma
Pan-tumor MRD Study
被験者募集中観察研究
- Northwest Medical Specialties (NWMS), Tacoma
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Tacoma
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
被験者募集中第3相
- Local Institution - 0499, Lacey · 23マイル先
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Research Site, Tacoma
- Research Site, Olympia · 26マイル先
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2/3相
- Vista Oncology - East Olympia /ID# 262303, Olympia · 26マイル先
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Tacoma
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
被験者募集中第1相
- Northwest Medical Specialties, Tacoma
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
被験者募集中第3相
- Research Site, Tacoma
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Exigent Research, LLC, Tacoma
- Northwest Medical Specialities, PLLC, Tacoma
- Northwest Medical Specialities. PLLC, Gig Harbor · 8マイル先
- 他3件
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
被験者募集中第3相
- MultiCare Institute for Research & Innovation, Tacoma
- MultiCare Regional Cancer Center, Gig Harbor · 8マイル先
- MultiCare Regional Cancer Center, Puyallup · 8マイル先
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
被験者募集中第2相
- USA09-0, Puyallup · 8マイル先
BostonGene and Exigent Genomic INsight Study
被験者募集中観察研究
- Northwest Medical Specialities, Puyallup · 8マイル先
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Tacomaにおける他の研究
- 乳がん18件の研究
- 潰瘍性大腸炎15件の研究
- 多発性骨髄腫13件の研究
- 前立腺がん11件の研究
- クローン病11件の研究
- 大腸癌9件の研究
- 転移性癌9件の研究
- 悪性黒色腫7件の研究
- 卵巣がん7件の研究
- 胃癌6件の研究
- 食道癌6件の研究
- がん（全種類）6件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。